

1 **Estimating historical disease burden and the impact of vaccination by influenza type and** 2 **subtype in the United States, 2016-2020**

3 Sinead E. Morris^{a,b,*}, Sarabeth M. Mathis^a, Jessie R. Chung^a, Brendan Flannery^a, Alissa O'Halloran^a,
4 Charisse N. Cummings^a, Shikha Garg^a, Peng-Jun Lu^c, Tammy A. Santibanez^c, Carrie Reed^a, Matthew
5 Biggerstaff^a, A. Danielle Iuliano^a

6
7 ^a*Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA, 30329*

8 ^b*Goldbelt Professional Services, Chesapeake, VA, USA, 23320*

9 ^c*Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA, USA, 30329*

10

11 ***Corresponding author:** run7@cdc.gov

12

13 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
14 represent the views of the Centers for Disease Control and Prevention.

15

16 **Highlights** (3-5 bullet points up to 85 characters each)

- 17 • Estimates of disease burden and vaccine-prevented burden inform influenza guidance.
- 18 • Contributions to burden from each virus type and subtype vary by season and age.
- 19 • A(H3N2) caused the greatest total disease burden from the 2016/17 to 2019/20 seasons.
- 20 • Children <18 years experienced greater influenza B burden compared with other ages.
- 21 • Vaccination against A(H1N1) and B prevented the greatest percentage of severe disease.

22

23 **Abstract**

24 Seasonal influenza causes substantial morbidity and mortality in the United States. The U.S. Centers for
25 Disease Control and Prevention (CDC) uses a compartmental framework to estimate the annual disease
26 burden and burden prevented by vaccination for all influenza types and subtypes combined. However,
27 these estimates do not capture underlying shifts in disease burden caused by different circulating
28 influenza virus types or subtypes. We demonstrate an extension of the current framework to estimate
29 disease burden and burden prevented by vaccination for influenza A virus subtypes A(H1N1) and
30 A(H3N2), and influenza type B viruses. We applied this method to data from the 2016/17 to 2019/20
31 seasons that include age- and virus-specific hospitalizations and vaccine effectiveness estimates, and
32 age-specific vaccination coverage estimates. We estimated the number of symptomatic illnesses,
33 medically-attended illnesses, hospitalizations, and deaths caused by each virus, and the corresponding
34 number prevented by vaccination. Disease burden and vaccine-prevented burden varied substantially by
35 season, age, and virus type or subtype. The greatest disease burden was estimated in 2017/18, whereas

36 2019/20 had the greatest burden prevented by vaccination. Influenza A viruses contributed most to
37 disease burden in all seasons. Vaccination against influenza B viruses prevented the largest percentage of
38 hospitalizations among children and adults <65 years, whereas vaccination against A(H1N1) prevented
39 the largest percentage of hospitalizations among adults ≥ 65 years. Overall, our results highlight complex
40 variability in influenza disease burden by season, age, and virus type and subtype. These findings can be
41 used to improve understanding of the factors impacting influenza disease burden each season and to
42 enhance communications of the value of influenza vaccination.

43

44 **Keywords:** vaccination; seasonal influenza; influenza subtype; disease burden; vaccine-preventable
45 burden

46

47 **Introduction**

48 Seasonal influenza viruses cause substantial morbidity and mortality in the United States. The U.S.
49 Centers for Disease Control and Prevention (CDC) estimates that between 9–41 million symptomatic
50 illnesses, 100,000–710,000 hospitalizations, and 5,000–52,000 deaths occur each year due to influenza¹.
51 Seasonal influenza vaccination is recommended for all persons ≥ 6 months old without contraindications
52 and prevents an estimated 1–7.5 million symptomatic illnesses, 22,000–100,000 hospitalizations and
53 1,000–12,000 deaths annually². Estimating influenza disease burden and the burden prevented by
54 vaccination is important for assessing the severity of seasonal influenza epidemics and communicating
55 the benefits of vaccination.

56 Currently, CDC estimates burden and burden prevented by vaccination using a compartmental
57 framework that models all influenza virus types and subtypes combined^{3,4}. However, these estimates do
58 not capture underlying shifts in disease burden caused by different influenza virus types (A vs. B) and
59 different influenza A subtypes (A(H1N1) vs. A(H3N2)) that can change seasonally due to complex
60 interactions between virus evolution, population immunity, and vaccine effectiveness (VE). Estimating
61 the different contributions of each type or subtype to overall disease burden and burden prevented by
62 vaccination could improve our understanding of the impact of influenza each season and its changing
63 epidemiological landscape.

64 In this paper, we demonstrate an extension of the current CDC framework to estimate disease
65 burden and burden prevented by vaccination by influenza virus type and subtype. We applied this
66 method to data from the 2016/17 to 2019/20 seasons that include age- and virus-specific
67 hospitalizations and VE estimates, and age-specific vaccination coverage estimates. Our method can be

68 combined with annual disease burden calculations to enhance communications of the risks of influenza
69 and the benefits of seasonal influenza vaccination.

70

71 **Methods**

72 *Surveillance data*

73 We used surveillance data spanning the 2016/17 to 2019/20 influenza seasons. Unless otherwise
74 specified, data were aggregated into six age groups: 0–6 months, 6 months–4 years, 5–17 years, 18–49
75 years, 50–64 years, and ≥65 years. Monthly numbers of laboratory-confirmed influenza-associated
76 hospitalizations were obtained from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a
77 population-based hospitalization surveillance network that represents approximately 29 million people
78 in the United States⁵. These data included the total number of hospitalizations, the number of
79 hospitalizations attributed to influenza A and influenza B, and the proportions of influenza A
80 hospitalizations that were attributed to A(H1N1) and A(H3N2) (Tables S1–S2, Figure S1). The latter
81 proportions incorporated imputed influenza A subtype information (which was originally missing for
82 approximately 55–60% of influenza A cases each season)^{6,7,8}. FluSurv-NET also provided information on
83 the total catchment population for each age group⁹. To account for under-ascertainment of laboratory
84 confirmed influenza hospitalizations, we calculated age-specific under-detection multipliers based on
85 testing practice information from FluSurv-NET sites and diagnostic test sensitivity⁹.

86 In addition to the distributions of virus type and subtype among influenza-associated
87 hospitalizations, we obtained corresponding distributions for laboratory-confirmed influenza-associated
88 outpatient visits from the US Influenza Vaccine Effectiveness (Flu VE) Network¹⁰ (Table S2, Figure S2).
89 Since this system recruits participants for vaccine effectiveness studies, there were no distributions for
90 infants aged 0–6 months (who are not eligible for influenza vaccination). We therefore assumed
91 distributions in that age group were equivalent to distributions among children aged 6 months–4 years.
92 We verified that the distributions from the Flu VE Network and FluSurv-NET were similar to independent
93 data obtained from the World Health Organization (WHO) and National Respiratory and Enteric Virus
94 Surveillance System (NREVSS) Collaborating Labs and reported to CDC's FluView (Figure S3)¹¹.

95 Finally, vaccine effectiveness estimates for A(H1N1), A(H3N2), influenza B, and all influenza
96 viruses combined were obtained from the Flu VE Network, and vaccine coverage estimates were
97 obtained from FluVaxView for all age groups ≥6 months¹² (Table S1, Figure S4). We approximated the
98 population size for each age group and season using US Census data¹³.


99

100 *Framework for estimating disease burden for influenza A(H1N1), A(H3N2), and B*

101 The methods employed by CDC to estimate disease burden and burden prevented by vaccination for all
102 influenza (i.e., for all viruses combined) have been described previously^{3,4,14–17} (Figure 1A). Briefly, the
103 monthly number of influenza-associated hospitalizations for each age group are first translated to rates
104 by dividing by the FluSurv-NET catchment population. These rates are then corrected for under-detection
105 of influenza-related hospitalizations and extrapolated to estimate total influenza hospitalizations in the
106 US population using the age-specific US census estimates. Numbers of symptomatic influenza illnesses
107 and deaths are obtained by multiplying the extrapolated number of hospitalizations by age-specific
108 ratios for the number of symptomatic influenza cases per hospitalization (case-hospitalization ratio) and
109 deaths per hospitalization (death-hospitalization ratio), respectively^{3,18,16}. The number of medically-
110 attended illnesses are obtained by multiplying the number of symptomatic illnesses by age-specific
111 estimates of the fraction of people with influenza-associated illness that seek medical care¹⁹. Values for
112 the under-detection, case-hospitalization, death-hospitalization, and medically-attended multipliers are
113 provided in Table S3.

114 We extended these methods to generate virus type- and subtype-specific estimates (Figure 1B).
115 For each month and age group, hospitalizations were attributed to either influenza A or B using the
116 relative proportions of each virus type in FluSurv-NET. Hospitalizations attributed to influenza A were
117 further partitioned by subtype using the relative proportions of A(H1N1) and A(H3N2). We used the
118 same type and subtype proportions to partition the total number of deaths into those attributable to
119 A(H1N1), A(H3N2) and B. For symptomatic and medically-attended illnesses, we instead used the relative
120 type and subtype proportions among Flu VE Network outpatient cases as these more accurately reflect
121 virus distributions among non-hospitalized cases of influenza. When presenting results, we combined
122 estimates for the two youngest age groups (0–6 months and 6 months–4 years) into all children aged 0–4
123 years.

124



125
 126 **Figure 1. Framework for estimating disease burden.** (A) Framework for estimating age-specific burden estimates
 127 for all influenza viruses. For each age group, reported hospitalizations rates are corrected for under-detection and
 128 extrapolated to the total population. These are then translated to estimates of deaths and symptomatic illnesses
 129 using age-specific death-hospitalization ratios and case-hospitalization ratios, respectively. Symptomatic illnesses
 130 are translated to medically-attended illnesses using age-specific estimates of the fraction that are medically-
 131 attended. (B) Burden estimates are translated to type or subtype specific estimates using virus distributions
 132 reported among influenza-positive hospitalizations (from FluSurv-NET) or outpatient cases (from the Flu VE
 133 Network).

134
 135 **Framework for estimating burden prevented by vaccination for influenza A(H1N1), A(H3N2) and B**
 136 For each virus type or subtype (A(H1N1), A(H3N2), B, or all influenza viruses combined), the monthly,
 137 age-specific estimates of disease burden were combined with estimates of vaccine coverage and
 138 effectiveness to estimate the burden prevented by vaccination following previously described methods⁴
 139 (Figure 2). We excluded the 0–6 months age group since they are ineligible for vaccination. The
 140 population was divided into three categories, susceptible, effectively vaccinated, and (symptomatically)
 141 infected as follows. For each age group, α , and type or subtype, i , the number effectively vaccinated (EV)
 142 in each successive month m is calculated as

143

$$EV_{\alpha,i,m} = (P_{\alpha} - \sum_{j=1}^m C_{\alpha,i,j-1}) \times VC_{\alpha,m} \times VE_{\alpha,i},$$

144 where P_{α} is the starting population size (assuming everyone is susceptible at the beginning of the
 145 season), $VC_{\alpha,m}$ is the proportion vaccinated in that month, $VE_{\alpha,i}$ is the vaccine effectiveness against type

146 or subtype i , and $\sum_{j=1}^m C_{a,i,j-1}$ is the cumulative number of symptomatic illnesses estimated during the
147 disease burden calculations and occurring up to the previous month (with $C_{a,i,0} = 0$). This formulation
148 assumes that vaccination provides all-or-nothing protection (i.e., individuals either gain complete
149 immunity following vaccination or remain entirely susceptible) and that susceptible and infected
150 individuals are equally likely to be vaccinated. The number susceptible (S) is then estimated as

$$151 \quad S_{a,i,m} = P_a - \sum_{j=1}^m C_{a,i,j} - \sum_{j=1}^m EV_{a,i,j},$$

152 with the implicit assumption that individuals can be infected by more than one virus type or subtype
153 within a season.

154 The risk of symptomatic illness (R) is the number of symptomatic illnesses that occurred in the
155 current month, m , divided by the susceptible (i.e., at-risk) population in the previous month, $m-1$,

$$156 \quad R_{a,i,m} = \frac{C_{a,i,m}}{S_{a,i,m-1}}.$$


157 Similarly, the risks of medically-attended illness, hospitalization, and death are approximated by dividing
158 the value in month m (estimated during the disease burden calculations) by the susceptible population
159 in month $m-1$. We use these risks to estimate the number of symptomatic illnesses, medically-attended
160 illnesses, hospitalizations, and deaths in the absence of vaccination. The estimated number of
161 symptomatic illnesses without vaccination, \hat{C} , is

$$162 \quad \hat{C}_{a,i,m} = \hat{S}_{a,i,m} \times R_{a,i,m},$$

163 where the susceptible population without vaccination, \hat{S} , is now calculated iteratively as

$$164 \quad \hat{S}_{a,i,m} = \hat{S}_{a,i,m-1} - \hat{C}_{a,i,m-1},$$

165 with $\hat{S}_{a,i,0} = P_a$ and $\hat{C}_{a,i,0} = 0$. The number of symptomatic illnesses prevented by vaccination is then
166 $\hat{C}_{a,i,m} - C_{a,i,m}$. Analogous calculations were used to estimate the number of medically-attended
167 illnesses, hospitalizations, and deaths prevented by vaccination. For each variable, age group, and type
168 or subtype, we calculated the sum of burden prevented by vaccination across all months in the season.
169 We also calculated disease burden prevented by vaccination as a percentage of the total estimated
170 disease burden in the absence of vaccination, for example, $\frac{\hat{C}_{a,i} - C_{a,i}}{\hat{C}_{a,i}} \times 100\%$. Finally, we note that
171 estimates of burden prevented by vaccination for all influenza viruses combined may not always equal
172 the sum of burden prevented for A(H1N1), A(H3N2), and B viruses because we use independent
173 estimates of VE in each calculation.



174
 175 **Figure 2. General framework for estimating disease burden prevented by vaccination within each age group and**
 176 **virus type or subtype for a given season.** Independent calculations are performed for each age group and virus
 177 type or subtype. The procedure is performed iteratively for each month (denoted by the subscript 'm').
 178 Abbreviations: VE = vaccine effectiveness.

179
 180 *Uncertainty distributions*
 181 We generated uncertainty distributions for each disease burden and vaccine-prevented burden estimate
 182 using Monte Carlo simulation methods described previously^{20,21,22}. Key input variables were each
 183 assigned a probability distribution (Table S4), from which we generated 10,000 independent samples.
 184 We then re-performed the disease burden and vaccine-prevented burden calculations for each sample
 185 and reported uncertainty as the 95th percentiles of the resulting distribution. All analyses were
 186 performed in R version 4.2.0²³ and resulting estimates are reported to three significant figures.

187
 188 **Results**

189 *Estimated disease burden*

190 For the 2016/17 to 2019/20 seasons, total estimated influenza disease burden ranged from 29.4–41.0
 191 million symptomatic illnesses, 13.6–18.9 million medically-attended illnesses, 395,000–710,000
 192 hospitalizations, and 22,100–51,800 deaths. The greatest number of hospitalizations and deaths


193 occurred in 2017/18 (Figure 3A), and across all seasons the greatest proportion of hospitalizations and
194 deaths occurred among adults ≥ 65 years (Figure S5).

195 Among virus types and subtypes, A(H3N2) caused the greatest cumulative burden from
196 2016/17–2019/20, with 59.0 million total symptomatic illnesses, 27.3 million medically-attended
197 illnesses, 1.12 million hospitalizations and 86,700 deaths (Table 1). However, the contribution of each
198 type and subtype to overall disease burden varied by season and age group (Figure 3, Figure S6).
199 Influenza A(H3N2) and B contributed most burden in 2016/17 and 2017/18, whereas A(H1N1) and
200 A(H3N2) contributed most burden in 2018/19, and A(H1N1) and B contributed most burden in 2019/20
201 (Figure 3A). For all age groups, influenza A viruses comprised the greatest proportion of burden across all
202 seasons, although the proportion attributed to influenza B viruses increased slightly among children < 18
203 years (Figure 3B).

204
205 **Table 1.** *Estimated disease burden by virus type or subtype. Numbers represent total estimated burden (and 95th*
206 *percentile uncertainty intervals) from 2016/17–2019/20 across all age groups and are reported to three significant*
207 *figures.*

Influenza type or subtype	Symptomatic illnesses (95 th uncertainty interval)	Medically-attended illnesses (95 th uncertainty interval)	Hospitalizations (95 th uncertainty interval)	Deaths (95 th uncertainty interval)
A(H1N1)	38.2 million (34.2–52.8 million)	17.4 million (15.7–23.4 million)	456,000 (393,000–685,000)	29,800 (20,600–66,500)
A(H3N2)	59.0 million (54.7–72.0 million)	27.3 million (25.5–33.4 million)	1.12 million (968,000–1.58 million)	86,700 (63,300–160,000)
B	36.7 million (33.5–48.9 million)	17.0 million (15.6–22.3 million)	411,000 (365,000–559,000)	27,200 (20,400–48,800)
All influenza	134 million (125–167 million)	61.7 million (58.0–76.0 million)	1.99 million (1.76–2.69 million)	144,000 (111,000–256,000)

208



209
 210 **Figure 3. Estimated disease burden.** (A) Point estimates of disease burden by type/subtype and season. (B)
 211 Distribution of type/subtypes causing burden in each age group, for all four seasons. Estimates by age group,
 212 season, and type/subtype, with corresponding 95th percentile uncertainty intervals, are shown in Figure S6.

213
 214 *Estimated burden prevented by vaccination*

215 Vaccine coverage was highest among children 6 months–4 years and adults ≥65 years, and during the
 216 2018/19 and 2019/20 seasons (Table S1, Figure S4A). VE varied substantially by season, age group, and
 217 virus type or subtype. Broadly, VE was highest in 2017/18 and lowest in 2018/19, decreased with
 218 increasing age, and was lower against A(H3N2) than A(H1N1) and B (Table S1, Figure S4B). One notable
 219 exception occurred in 2019/20, when adults ≥65 years experienced relatively high VE against A(H1N1)
 220 and A(H3N2).


221 From 2016/17 to 2019/20, total estimated burden prevented by vaccination ranged from 2.85–
 222 6.74 million symptomatic illnesses, 1.49–3.28 million medically-attended illnesses, 35,800–98,500
 223 hospitalizations, and 2,520–6,370 deaths. The greatest burden prevented by vaccination occurred in
 224 2019/20 (Figure 4A). For all seasons, the greatest number of hospitalizations were prevented among
 225 adults ≥65 years, whereas the greatest percent of hospitalizations were generally prevented among
 226 children 6 months–4 years (Figure S7).

227 Among type and subtypes, the largest cumulative number of hospitalizations and deaths were
228 prevented by vaccination against influenza A(H3N2), whereas the largest number of symptomatic and
229 medically-attended illnesses were prevented by vaccination against influenza B (Table 2). In line with our
230 disease burden estimates, vaccination against influenza A(H3N2) and B prevented most burden in
231 2016/17 and 2017/18, whereas vaccination against A(H1N1) and A(H3N2) prevented most burden in
232 2018/19, and vaccination against A(H1N1) and B prevented most burden in 2019/20 (Figure 4A, Figure
233 S8). Among seasons, the percent of hospitalizations prevented was generally highest for A(H1N1) and B,
234 with substantially lower percentages for A(H3N2) (except in 2019/20 when the overall burden of
235 A(H3N2) was low) (Figure 4B). This was also true among age groups, with vaccination against influenza B
236 preventing the highest percentage of hospitalizations among children and adults <65 years, and
237 vaccination against A(H1N1) preventing the highest percentage among adults ≥65 years (Figure 4C).

238
239 **Table 2.** *Estimated vaccine-prevented disease burden by virus type or subtype. Numbers represent total prevented*
240 *disease burden (and 95th percentile uncertainty intervals) from 2016/17–2019/20 across all age groups and are*
241 *reported to three significant figures.*

Influenza type or subtype	Symptomatic illnesses (95 th uncertainty interval)	Medically-attended illnesses (95 th uncertainty interval)	Hospitalizations (95 th uncertainty interval)	Deaths (95 th uncertainty interval)
A(H1N1)	7.28 million (6.19–9.83 million)	3.62 million (3.10–4.81 million)	99,500 (71,100–172,000)	6,720 (3,780–17,100)
A(H3N2)	5.45 million (4.75–7.76 million)	2.83 million (2.45–4.05 million)	106,000 (75,000–195,000)	8,050 (4,750–19,500)
B	8.47 million (7.36–11.3 million)	4.19 million (3.64–5.55 million)	90,700 (70,100–131,000)	5,550 (3,540–10,500)
All influenza	20.9 million (18.9–27.0 million)	10.6 million (9.54–13.6 million)	289,000 (233,000–439,000)	19,400 (13,100–39,000)

242



243
 244 **Figure 4.** Estimated burden prevented by vaccination. (A) Point estimates for total averted burden by type/subtype
 245 and season. (B) Percent of hospitalizations averted by type/subtype and season (for all age groups). (C) Percent of
 246 hospitalizations averted by type/subtype and age group (across all four seasons). Estimates by age group, season,
 247 and type or subtype, with corresponding 95th percentile uncertainty intervals, are shown in Figure S8.
 248

249 Discussion

250 In this paper, we have demonstrated an extension to current CDC methods for estimating disease burden
 251 and burden prevented by vaccination for influenza that partitions burden among different influenza virus
 252 types and subtypes. During the 2016/17 to 2019/20 seasons, we estimated substantial influenza-
 253 associated disease burden and burden prevented by vaccination. In general, influenza A viruses were the
 254 greatest contributor to disease burden, particularly A(H3N2), and children <18 years were more
 255 impacted by influenza B viruses than other age groups. The greatest percentage of hospitalizations were
 256 prevented by vaccination against influenza A(H1N1) and B viruses. Overall, our framework can improve
 257 understanding of the impact of influenza each season and enhance communications of the benefits of
 258 influenza vaccination.

259 There are many factors that can affect disease burden and vaccine-prevented burden each
 260 season, including virus evolution and strain circulation dynamics, VE and vaccine coverage, population
 261 immunity from prior seasons, prevalence of underlying health conditions, and other factors influencing

262 transmission dynamics (for example, individual behavior). Lower VE for A(H3N2) viruses compared to
263 A(H1N1) and B viruses may explain why we estimated the greatest disease burden and lowest percent of
264 burden prevented by vaccination for A(H3N2). Similarly, a combination of relatively high vaccine
265 coverage and VE against A(H1N1) among older age groups in 2019/20 may partly explain the high levels
266 of vaccine-prevented burden estimated in that season. More generally, our framework provides a path to
267 explore how these interacting factors combine to impact the burden of influenza and impact of
268 vaccination at the population-level.

269 Limitations to the CDC method for estimating burden and vaccine-prevented burden for all
270 influenza viruses have been discussed previously^{3,4}. These include caveats that the framework assumes
271 protection from vaccination is ‘all-or-nothing’, uses one value for VE against all outcomes, and does not
272 account for indirect protection through herd immunity or waning immunity. With respect to data inputs,
273 the vaccination coverage information was based on self- (or parent-) assessment and may be subject to
274 recall bias, although previous work has found good agreement between self-reported vaccination status
275 among adults and vaccination status ascertained from medical records²⁴. In addition, the FluSurv-NET
276 surveillance system covers approximately 9% of the U.S. population and may not be representative of
277 the population as a whole. Influenza A subtype was also imputed for approximately 55-60% of influenza
278 A hospitalizations each season and could be subject to misclassification, although the rates of this are
279 expected to be low^{6,8}. Finally, the case-hospitalization ratio and fraction of cases that seek medical care
280 were estimated during the 2009 H1N1 pandemic and will not reflect any changes to care-seeking and
281 hospital admission rates that have occurred since then.

282 When extending the method to account for virus type and subtype there are several further
283 limitations to consider. First, we assumed the case-hospitalization ratios and care-seeking fractions were
284 equal for influenza A(H1N1), A(H3N2) and B. Further information on whether care-seeking and rates of
285 hospital admission change by virus type and subtype would be needed to incorporate this into our
286 extended framework. Secondly, by running independent models for each type and subtype, we implicitly
287 assumed that an individual could be infected by multiple viruses within the same season. Although this
288 assumption ignores any cross-immunity between A(H1N1), A(H3N2), or B viruses, we expect the
289 individual-level risk of being infected by more than one influenza virus to be relatively low within a
290 season and thus our results should not be substantially impacted. Finally, we did not partition estimates
291 of disease burden or vaccine-prevented burden by influenza B lineages (B/Yamagata and B/Victoria) as
292 the hospitalization and outpatient data did not contain this information. We have explored additional
293 methods to partition estimates by influenza B lineage in related work²⁵.

294 Here we have demonstrated how existing methods to estimate the disease burden and vaccine-
295 prevented burden of influenza can be extended to estimate contributions from different virus types and
296 subtypes. We found substantial disease burden and vaccine-prevented burden for all influenza types and
297 subtypes across seasons and age groups, underscoring the importance of annual influenza vaccination.
298 This is particularly relevant given recent declines in influenza vaccine coverage since the COVID-19
299 pandemic¹². In addition, our results included complex variability by season, age, and vaccine coverage
300 and effectiveness, and can be used to track changes in influenza strain dynamics in future seasons while
301 enhancing our understanding of the burden of influenza viruses and impact of vaccination.

302

303 **Funding:** This research did not receive any specific grant from funding agencies in the public,
304 commercial, or not-for-profit sectors.

305

306 **Conflicts of Interest:** The authors have no competing interests to declare.

307

308 **Acknowledgments:** The authors thank Anup Srivastav, Anurag Jain, and Mei-Chuan Hung for their
309 contributions to obtaining the vaccination coverage estimates.

310

311 **Author Contributions:** All authors attest they meet the ICMJE criteria for authorship.

312

313 **Data availability statement:** All data were the result of secondary analyses and used solely as model
314 inputs. The majority are publicly available, and the relevant links are cited in the text. A small portion are
315 not publicly available due to privacy restrictions but are available upon reasonable request to the
316 authors.

317

318 **References**

319 1. CDC. About Estimated Flu Burden. 2024. Accessed October 4, 2024. [https://www.cdc.gov/flu-](https://www.cdc.gov/flu-burden/php/about/index.html)
320 [burden/php/about/index.html](https://www.cdc.gov/flu-burden/php/about/index.html)

321 2. CDC. Flu Burden Prevented by Vaccination. 2024. Accessed October 4, 2024. [https://www.cdc.gov/flu/vaccines-](https://www.cdc.gov/flu/vaccines-work/burden-prevented.htm)
322 [work/burden-prevented.htm](https://www.cdc.gov/flu/vaccines-work/burden-prevented.htm)

323 3. Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of seasonal influenza in the United States: A
324 tool for strengthening influenza surveillance and preparedness. *Influenza Other Respir Viruses*.
325 2018;12(1):132-137. doi:10.1111/irv.12486

- 326 4. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of
327 influenza cases averted by vaccination in the United States. *Vaccine*. 2018;36(48):7331-7337.
328 doi:10.1016/j.vaccine.2018.10.026
- 329 5. CDC. Influenza Hospitalization Surveillance Network (FluSurv-NET). 2024. Accessed April 29, 2024.
330 <https://www.cdc.gov/fluview/overview/influenza-hospitalization-surveillance.html>
- 331 6. Sumner KM, Masalovich S, O'Halloran A, et al. Severity of influenza-associated hospitalisations by influenza virus
332 type and subtype in the USA, 2010–19: a repeated cross-sectional study. *Lancet Microbe*. 2023;4(11):e903-
333 e912. doi:10.1016/S2666-5247(23)00187-8
- 334 7. Chow EJ, Rolfes MA, O'Halloran A, et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized
335 Adults. *Ann Intern Med*. 2020;173(8):605-613. doi:10.7326/M20-1509
- 336 8. Holstein R, Dawood FS, O'Halloran A, et al. Characteristics and Outcomes of Hospitalized Pregnant Women With
337 Influenza, 2010 to 2019. *Ann Intern Med*. 2022;175(2):149-158. doi:10.7326/M21-3668
- 338 9. Millman AJ, Reed C, Kirley PD, et al. Improving Accuracy of Influenza-Associated Hospitalization Rate Estimates.
339 *Emerg Infect Dis*. 2015;21(9):1595-1601. doi:10.3201/eid2109.141665
- 340 10. CDC. US Flu VE Network. 2023. Accessed March 26, 2024. [https://www.cdc.gov/flu-vaccines-work/php/vaccine-](https://www.cdc.gov/flu-vaccines-work/php/vaccine-effectiveness/us-flu-ve-network.html)
341 [effectiveness/us-flu-ve-network.html](https://www.cdc.gov/flu-vaccines-work/php/vaccine-effectiveness/us-flu-ve-network.html)
- 342 11. CDC. FluView Interactive. 2023. Accessed February 14, 2024. [https://www.cdc.gov/fluview/overview/fluview-](https://www.cdc.gov/fluview/overview/fluview-interactive.html)
343 [interactive.html](https://www.cdc.gov/fluview/overview/fluview-interactive.html)
- 344 12. CDC. FluVaxView. 2023. Accessed February 14, 2024. <https://www.cdc.gov/fluvoxview/>
- 345 13. US Census Bureau. National Population by Characteristics: 2010-2019. 2021. Accessed March 26, 2024.
346 <https://www.census.gov/data/datasets/time-series/demo/popest/2010s-national-detail.html>
- 347 14. CDC. How CDC Estimates the Burden of Flu Prevented by Vaccination. 2024. Accessed October 4, 2024.
348 <https://www.cdc.gov/flu-burden/php/about-burden-prevented/how-cdc-estimates-vaccinations.html>
- 349 15. CDC. How CDC Estimates the Burden of Seasonal Flu in the United States. 2023. Accessed October 4, 2024.
350 <https://www.cdc.gov/flu-burden/php/about/how-cdc-estimates.html>
- 351 16. Reed C, Chaves SS, Kirley PD, et al. Estimating Influenza Disease Burden from Population-Based Surveillance
352 Data in the United States. *PLOS ONE*. 2015;10(3):e0118369. doi:10.1371/journal.pone.0118369
- 353 17. Kostova D, Reed C, Finelli L, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the
354 United States, 2005–2011. *PLOS ONE*. 2013;8(6):e66312. doi:10.1371/journal.pone.0066312
- 355 18. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States,
356 April–July 2009. *Emerg Infect Dis*. 2009;15(12):2004-2007. doi:10.3201/eid1512.091413
- 357 19. Biggerstaff M, Jhung M, Kamimoto L, Balluz L, Finelli L. Self-Reported Influenza-Like Illness and Receipt of
358 Influenza Antiviral Drugs During the 2009 Pandemic, United States, 2009–2010. *Am J Public Health*.
359 2012;102(10):e21-e26. doi:10.2105/AJPH.2012.300651
- 360 20. Rolfes MA, Flannery B, Chung JR, et al. Effects of Influenza Vaccination in the United States During the 2017–
361 2018 Influenza Season. *Clin Infect Dis*. 2019;69(11):1845-1853. doi:10.1093/cid/ciz075

- 362 21. Steele MK, Couture A, Reed C, et al. Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths
363 Prevented Among Vaccinated Persons in the US, December 2020 to September 2021. *JAMA Netw Open*.
364 2022;5(7):e2220385. doi:10.1001/jamanetworkopen.2022.20385
- 365 22. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United States During the 2018-
366 2019 Influenza Season. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;71(8):e368-e376.
367 doi:10.1093/cid/ciz1244
- 368 23. R Core Team. R: A language and environment for statistical computing. Published online 2022. [https://www.R-](https://www.R-project.org/)
369 [project.org/](https://www.R-project.org/)
- 370 24. Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult
371 vaccines: Do results vary by demographic factors? *Vaccine*. 2013;31(37):3928-3935.
372 doi:10.1016/j.vaccine.2013.06.041
- 373 25. Morris SE, Mathis SM, Chung JR, et al. Estimating historical impacts of vaccination against influenza B/Yamagata
374 in the United States to inform possible risks of re-emergence in the absence of vaccination. *medRxiv*.
375 Published online October 30, 2024:2024.10.30.24316093. doi:10.1101/2024.10.30.24316093
- 376